Daiichi Sankyo Moves Six Disease Programs To India For Discovery
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has moved six drug-discovery programs, those dealing with infectious and inflammatory diseases, to its R&D hub in India